| 1 |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315 (8): 801-810.
|
| 2 |
Nesseler N, Launey Y, Aninat C, et al. Clinical review: the liver in sepsis[J]. Crit Care, 2012, 16 (5): 235.
|
| 3 |
Bates DW, Sands K, Miller E, et al. Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group[J]. J Infect Dis, 1997, 176 (6): 1538-1551.
|
| 4 |
Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference[J]. Crit Care Med, 2003, 31 (4): 1250-1256.
|
| 5 |
Grozdanovski K, Milenkovikj Z, Demiri I, et al. Epidemiology of community-acquired sepsis in adult patients: a six year observational study[J]. Pril (Makedon Akad Nauk Umet Odd Med Nauki), 2018, 39 (1): 59-66.
|
| 6 |
Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial[J]. Crit Care Med, 2003, 31 (3): 834-840.
|
| 7 |
Bakker J, Grover R, McLuckie A, et al. Administration of the nitric oxide synthase inhibitor NG-methyl-Larginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)[J]. Crit Care Med, 2004, 32 (1): 1-12.
|
| 8 |
Kobashi H, Toshimori J, Yamamoto K. Sepsis-associated liver injury: incidence, classification and the clinical significance[J]. Hepatol Res, 2013, 43 (3): 255-266.
|
| 9 |
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013, 39 (2): 165-228.
|
| 10 |
Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome[J]. Crit Care Med, 1995, 23 (10): 1638-1652.
|
| 11 |
Sakka SG. Assessment of liver perfusion and function by indocyanine green in the perioperative setting and in critically ill patients[J]. J Clin Monit Comput, 2018, 32 (5): 787-796.
|
| 12 |
Woznica EA, Inglot M, Woznica RK, et al. Liver dysfunction in sepsis[J]. Adv Clin Exp Med, 2018, 27 (4): 547-551.
|
| 13 |
European Association for the Study of the Liver EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J]. J Hepatol, 2017, 66 (5): 1047-1081.
|
| 14 |
Tian T, Tian W, Yang F, et al. Sphingosine kinase 1 inhibition improves lipopolysaccharide/D-galactosamine-induced acute liver failure by inhibiting mitogen-activated protein kinases pathway[J]. United European Gastroenterol J, 2016, 4 (5): 677-685.
|
| 15 |
刘蕾，刘芙蓉，资双凤，等.自噬在脓毒症器官功能障碍中的研究现状[J/CD].中华危重症医学杂志（电子版），2019，12（3）：194-198.
|
| 16 |
Brusletto BS, Loberg EM, Hellerud BC, et al. Extensive changes in transcriptomic "fingerprints" and immunological cells in the large organs of patients dying of acute septic shock and multiple organ failure caused by Neisseria meningitidis[J]. Front Cell Infect Microbiol, 2020 (10): 42.
|
| 17 |
Bernal W, Wendon J. Acute liver failure[J]. N Engl J Med, 2013, 369 (26): 2525-2534.
|
| 18 |
Bernal W, Auzinger G, Dhawan A, et al. Acute liver failure[J]. Lancet, 2010, 376 (9736): 190-201.
|
| 19 |
吴月，杨云梅.微RNA-155激动剂对脓毒症小鼠肝损伤时炎症应答的影响[J/CD].中华危重症医学杂志（电子版），2019，12（4）：235-239.
|
| 20 |
Strnad P, Tacke F, Koch A, et al. Liver-guardian, modifier and target of sepsis[J]. Nat Rev Gastroenterol Hepatol, 2017, 14 (1): 55-66.
|
| 21 |
Bock KW. Regulation of bilirubin clearance by ligand-activated transcription factors of the endo- and xenobiotic metabolism system[J]. Front Pharmacol, 2011 (2): 82.
|
| 22 |
Chand N, Sanyal AJ. Sepsis-induced cholestasis[J]. Hepatology, 2007, 45 (1): 230-241.
|
| 23 |
Bhogal HK, Sanyal AJ. The molecular pathogenesis of cholestasis in sepsis[J]. Front Biosci (Elite Ed), 2013 (5): 87-96.
|
| 24 |
Waseem N, Chen PH. Hypoxic hepatitis: a review and clinical update[J]. J Clin Transl Hepatol, 2016, 4 (3): 263-268.
|